Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 8/20 | 0.49 |
| ▸ | QDPR | P09417 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | KHK | P50053 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5817998 | 0.83 | TDP1 (0.57) | SIGMAR1HTR2CQDPRALDH1A1KHK | |
| SCHEMBL5064343 | 0.81 | QDPR (0.49) | SIGMAR1HTR2CQDPRKHKMAPT | |
| Hydrochloric Acid SCHEMBL31091839 | 0.80 | QDPR (0.48) | SIGMAR1HTR2CQDPRKHKMAPT | |
| SCHEMBL3383939 | 0.79 | HTR2C (0.62) | SIGMAR1HTR2CQDPRKHKHTR6 | |
| SCHEMBL3435634 | 0.78 | HTR6 (0.44) | SIGMAR1HTR2CQDPRALDH1A1MAPT | |
| SCHEMBL522135 | 0.77 | QDPR (0.62) | SIGMAR1HTR2CQDPRALDH1A1KHK | |
| SCHEMBL4789631 | 0.77 | HTR2C (0.56) | SIGMAR1HTR2CQDPRKHKHTR6 | |
| Hydrochloric Acid SCHEMBL6371753 | 0.77 | HTR2C (0.64) | SIGMAR1HTR2CQDPRKHKHTR6 | |
| Hydrochloric Acid SCHEMBL521660 | 0.76 | QDPR (0.61) | SIGMAR1HTR2CQDPRALDH1A1KHK | |
| SCHEMBL28538188 | 0.76 | MAPT (0.49) | SIGMAR1HTR2CQDPRALDH1A1KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1708704-A4 | 4-ARYL PIPERIDINES | LUNDBECK & CO AS H (DK) | 2009-08-05 | — | — | EP | disclosed |
| EP-1708704-A2 | 4-ARYL PIPERIDINES | H.Lundbeck A/S (DK) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005069834-A2 | 4-ARYL PIPERIDINES | H. LUNDBECK A/S (DK) | 2005-08-04 | — | — | WO | disclosed |
| US-20050154020-A1 | 4-Aryl piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154020-A1 | 4-Aryl piperidines | MCHR1, MCHR2, MC1R | SIGMAR1 94/4885HTR2C 26/4885QDPR 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.